Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) – Research analysts at Wedbush boosted their FY2019 EPS estimates for Catabasis Pharmaceuticls in a note issued to investors on Tuesday. Wedbush analyst L. Moussatos now forecasts that the firm will post earnings per share of ($2.65) for the year, up from their previous forecast of ($2.83). Wedbush currently has a “Outperform” rating and a $17.00 price target on the stock.
A number of other analysts have also weighed in on CATB. Cowen and Company restated a “buy” rating on shares of Catabasis Pharmaceuticls in a research note on Wednesday, June 8th. Zacks Investment Research upgraded Catabasis Pharmaceuticls from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research note on Tuesday, July 5th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Catabasis Pharmaceuticls presently has a consensus rating of “Buy” and a consensus price target of $19.05.
Shares of Catabasis Pharmaceuticls (NASDAQ:CATB) traded up 0.18% during trading on Thursday, hitting $5.44. The stock had a trading volume of 223,049 shares. The firm has a 50 day moving average of $4.76 and a 200 day moving average of $4.76. Catabasis Pharmaceuticls has a 1-year low of $3.31 and a 1-year high of $10.83. The company’s market capitalization is $83.67 million.
Catabasis Pharmaceuticls (NASDAQ:CATB) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.04.
A hedge fund recently raised its stake in Catabasis Pharmaceuticls stock. Sphera Funds Management LTD. boosted its stake in shares of Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) by 184.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 230,041 shares of the company’s stock after buying an additional 149,299 shares during the period. Sphera Funds Management LTD. owned 1.50% of Catabasis Pharmaceuticls worth $1,159,000 as of its most recent SEC filing. 57.27% of the stock is owned by hedge funds and other institutional investors.
About Catabasis Pharmaceuticls
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related companies with MarketBeat.com's FREE daily email newsletter.